Medical Greens Announces Development of New T-Hydrocan Medical Cannabis Product Line

Marketwired

LOS ANGELES, CA--(Marketwired - Nov 25, 2013) - SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary Medical Greens announces its newest product, T-Hydrocan™, a new medicinal cannabis product line. While the focus of SK3's Berkeley Bio's endeavors lies in the development of potential treatments for cancer utilizing non-psychoactive elements of the cannabis/hemp plant, as reflected in the recently-announced Dharmanol™ product line, many patients have found considerable benefit from oral administration of THC, the psychoactive element found in the cannabis / hemp plant, when used to treat a wide variety of medical conditions.

A synthetic version of THC, Marinol™ has been available by prescription for many years, and is prescribed to remediate the pain and nausea from cancer and the side effects of radiation and chemotherapy. Interestingly, Marinol™ is routinely prescribed to cancer patients, and those who also have access to similar natural cannabis products greatly prefer the natural products over the synthetic pharmaceuticals.

T-Hydrocan™ tablets contain the psychoactive element THC, as well as the complete array of cannabinoids that are naturally present in the cannabis / hemp plant. In addition to the cannabinoids, T-Hydrocan™ tablets contain a steam-distilled extract of cannabis / hemp, containing the natural terpenes and terpenoids which work synergistically with the cannabinoids.

Several different versions of T-Hydrocan™ will be offered, adjusting the basic T-Hydrocan™ formula for different applications. T-Hydrocan™ Whole-Plant™ will contain psychoactive, decarboxylated THC, as well as the entire array of related medicinal elements found in the cannabis / hemp plant. T-Hydrocan™ Citrolene™ will contain a healthy dose of the terpene d-Limonene, which attaches to the same receptors as do tranquilizers such as Valium and Xanax, adding a natural relaxing element to the medicine. T-Hydrocan -- CBD™ will add an amount of CBD equal to the THC.

The T-Hydrocan™ line of cannabis-based medicinals will be available through the dispensaries and collectives that have partnered with Medical Greens' wholesale managed collectives.

"We are pleased to add this new product to the arsenal of products available through Medical Greens to fight cancer and we look forward to adding many more," said President Artemus Mayor. "We expect this product to contribute significantly to the growth of the Company as it meets this underserved market."

FDA Statement
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.

About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
SK3 Group, Inc.
investors@medicalgreens.com
Investor Relations
View Comments (0)